In 2021, Hologic acquired Biotheranostics, expanding its oncology services with the Breast Cancer Index test. At the 2025 SABCS, new studies highlight the test’s potential in treatment decisions for HR+ breast cancer patients. The BCI test has led to treatment changes for 40% of patients, boosting physician confidence and patient comfort.

Medtronic gains FDA clearance for its Hugo robotic surgery system for urologic procedures. BDX releases new cell analyzers with advanced imaging technologies. Hologic’s stock has grown by 18.9% in the past six months. Hologic is trading at a lower P/S ratio than the industry average, with analysts projecting future earnings.

Discover the top stock with potential to double, handpicked by Zacks’ Director of Research. Get insights on other top stock recommendations with money-doubling potential. Access free stock analysis reports on BDX, MDT, and HOLX. Stay updated with the latest stock recommendations from Zacks Investment Research.

Read more at Nasdaq: Hologic’s BCI Test Shows Growing Impact in Endocrine Therapy Decisions